- Home
- QSI vs FENC Comparison
QSI vs FENC Comparison
Compare QSI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | FENC |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | 145 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.8M | 230.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | QSI | FENC |
|---|---|---|
| Price | $1.04 | $8.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.00 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 6.9M | 379.7K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | $618.07 | $41.08 |
| P/E Ratio | ★ N/A | $916.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.69 | $5.65 |
| 52 Week High | $3.10 | $10.45 |
Technical Indicators
Market Signals| Indicator | QSI | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 49.22 |
| Support Level | $0.88 | $7.40 |
| Resistance Level | $1.08 | $9.15 |
| Average True Range (ATR) | 0.11 | 0.53 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 45.26 | 5.85 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.